BeOne Medicines (ONC) Non-Current Debt (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Non-Current Debt of $842.9 million for Q1 2026, up 426.31% year-over-year from $160.2 million in Q1 2025, and down 12.37% quarter-over-quarter from $961.9 million in Q4 2025.
BeOne Medicines (ONC) Non-Current Debt (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Non-Current Debt for 12 consecutive years, with $842.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt rose 426.31% year-over-year to $842.9 million; the TTM figure through Mar 2026 stood at $842.9 million (up 426.31% YoY), while the FY2025 annual figure was $961.9 million, up 477.78% from the prior year.
- Non-Current Debt retreated to $842.9 million in Q1 2026 per ONC's latest filing, from $961.9 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $961.9 million in Q4 2025 and bottomed at $139.6 million in Q3 2025.
- Historically, Non-Current Debt has averaged $271.0 million across 5 years, with a median of $199.0 million in 2024.
- On a YoY basis, Non-Current Debt climbed as much as 477.78% in 2025 and fell as far as 25.57% in 2025.
- BeOne Medicines' Non-Current Debt stood at $209.1 million in 2022, then slipped by 5.51% to $197.6 million in 2023, then decreased by 15.75% to $166.5 million in 2024, then soared by 477.78% to $961.9 million in 2025, then retreated by 12.37% to $842.9 million in 2026.
- Business Quant data shows ONC's Non-Current Debt at $842.9 million in Q1 2026, $961.9 million in Q4 2025, and $139.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 882.16 Mn |
| Mar 31, 2026 | 842.92 Mn |
| Dec 31, 2025 | 961.91 Mn |
| Sep 30, 2025 | 139.57 Mn |
| Jun 30, 2025 | 146.09 Mn |
| Mar 31, 2025 | 160.16 Mn |
| Dec 31, 2024 | 166.48 Mn |
| Sep 30, 2024 | 187.51 Mn |
| Jun 30, 2024 | 185.27 Mn |
| Mar 31, 2024 | 199.03 Mn |
| Dec 31, 2023 | 197.62 Mn |
| Sep 30, 2023 | 202.49 Mn |
| Jun 30, 2023 | 207.43 Mn |
| Mar 31, 2023 | 206.30 Mn |
| Dec 31, 2022 | 209.15 Mn |
| Sep 30, 2022 | 208.06 Mn |
| Jun 30, 2022 | 185.21 Mn |
| Mar 31, 2022 | 201.61 Mn |
| Dec 31, 2021 | 202.11 Mn |
| Sep 30, 2021 | 200.91 Mn |